Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma
- 1 January 2012
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 124 (1), 148-152
- https://doi.org/10.1016/j.ygyno.2011.09.037
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Gene Expression Profiles in Stage I Uterine Serous Carcinoma in Comparison to Grade 3 and Grade 1 Stage I Endometrioid AdenocarcinomaPLOS ONE, 2011
- Pure Papillary Serous Tumors of the EndometriumInternational Journal of Gynecologic Cancer, 2009
- Endometrial Cancer State of the Science MeetingInternational Journal of Gynecologic Cancer, 2009
- Expression of γ-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116World Journal of Gastroenterology, 2009
- Novel molecular profiles of endometrial cancer—new light through old windowsThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Neuronal protein synuclein γ predicts poor clinical outcome in breast cancerInternational Journal of Cancer, 2007
- γ‐Synuclein and the progression of cancerThe FASEB Journal, 2007
- Synuclein-γ Targeting Peptide Inhibitor that Enhances Sensitivity of Breast Cancer Cells to Antimicrotubule DrugsCancer Research, 2007
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK PathwaysPublished by Elsevier BV ,2002